Pamela M Pollock

List of Publications by Year in Descending Order

62 papers	9,486 citations	35 h-index	66 g-index
66 ext. papers	11,040 ext. citations	10.5 avg, IF	5.13 L-index

#	Paper	IF	Citations
62	Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer.. *Genome Medicine*, **2022**, 14, 3	14.4	2
61	Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progestin Therapy in Atypical Hyperplasia and Low-Grade Endometrial Cancer. *Cancers*, **2021**, 13,	6.6	2
60	FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes. *Clinical Cancer Research*, **2020**, 26, 4569-4580	12.9	3
59	Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer. *Theranostics*, **2020**, 10, 2095-2114	12.1	10
58	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. *Journal of Clinical Oncology*, **2020**, 38, 3388-3397	2.2	116
57	Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer. *Molecular Oncology*, **2019**, 13, 738-756	7.9	7
56	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. *Modern Pathology*, **2018**, 31, 1851-1861	9.8	24
55	FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models. *Journal of Cell Science*, **2018**, 131,	5.3	11
54	PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2 Endometrial Cancers. *Molecular Cancer Therapeutics*, **2017**, 16, 637-648	6.1	26
53	Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative. *Gynecologic Oncology*, **2017**, 146, 327-333	4.9	16
52	FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. *Gynecologic Oncology*, **2017**, 145, 366-373	4.9	26
51	Loss of Rearranged L-Myc Fusion (RLF) results in defects in heart development in the mouse. *Differentiation*, **2017**, 94, 8-20	3.5	6
50	Immunological profiling of molecularly classified high-risk endometrial cancers identifies -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. *OncoImmunology*, **2017**, 6, e1264565	7.2	79
49	hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases. *DNA Repair*, **2017**, 54, 30-39	4.3	9
48	Endometrial cancer cells exhibit high expression of p110□and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. *Oncotarget*, **2017**, 8, 3881-3894	3.3	10
47	A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding. *American Journal of Human Genetics*, **2016**, 98, 1159-1169	11	17
46	The "melanoma-enriched" microRNA miR-4731-5p acts as a tumour suppressor. *Oncotarget*, **2016**, 7, 49677-49687	3.3	18

45	The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. *EBioMedicine*, **2015**, 2, 671-80	8.8	67
44	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. *Modern Pathology*, **2015**, 28, 836-44	9.8	222
43	Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents. *Cancer Discovery*, **2015**, 5, 355-7	24.4	15
42	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. *Human Molecular Genetics*, **2015**, 24, 1478-92	5.6	46
41	miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. *Oncotarget*, **2015**, 6, 17753-63	3.3	65
40	A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. *Gynecologic Oncology*, **2014**, 135, 38-43	4.9	67
39	The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. *Neoplasia*, **2013**, 15, 975-88	6.4	98
38	Integrated genomic characterization of endometrial carcinoma. *Nature*, **2013**, 497, 67-73	50.4	2800
37	XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. *Anti-Cancer Drugs*, **2013**, 24, 181-8	2.4	36
36	Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. *Molecular Cancer*, **2012**, 11, 75	42.1	30
35	Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells. *International Journal of Gynecological Cancer*, **2012**, 22, 1517-26	3.5	19
34	Lineage-specific biomarkers predict response to FGFR inhibition. *Cancer Discovery*, **2012**, 2, 1081-3	24.4	1
33	FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. *PLoS ONE*, **2012**, 7, e30801	3.7	122
32	Targeting mutant fibroblast growth factor receptors in cancer. *Trends in Molecular Medicine*, **2011**, 17, 283-92	11.5	96
31	Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734. *Journal of Biological Chemistry*, **2011**, 286, 42303-42315	5.4	29
30	p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. *Pigment Cell and Melanoma Research*, **2010**, 23, 781-94	4.5	50
29	FGFR2 mutations are rare across histologic subtypes of ovarian cancer. *Gynecologic Oncology*, **2010**, 117, 125-9	4.9	38
28	Active Notch1 confers a transformed phenotype to primary human melanocytes. *Cancer Research*, **2009**, 69, 5312-20	10.1	93

27	Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. *Molecular and Cellular Biology*, **2009**, 29, 4663-78	4.8	33
26	Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. *Molecular Cancer Research*, **2009**, 7, 41-54	6.6	100
25	FGFR2 as a molecular target in endometrial cancer. *Future Oncology*, **2009**, 5, 27-32	3.6	49
24	A crystallographic snapshot of tyrosine trans-phosphorylation in action. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 19660-5	11.5	49
23	Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk. *Human Reproduction*, **2008**, 23, 1661-8	5.7	12
22	Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. *Cancer Research*, **2008**, 68, 6902-7	10.1	124
21	Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. *Clinical Cancer Research*, **2008**, 14, 6146-53	12.9	195
20	Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. *Oncogene*, **2007**, 26, 7158-62	9.2	254
19	Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. *Carcinogenesis*, **2006**, 27, 1778-86	4.6	49
18	Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. *Cancer Research*, **2005**, 65, 6282-93	10.1	261
17	Microarray expression profiling in melanoma reveals a BRAF mutation signature. *Oncogene*, **2004**, 23, 4060-7	9.2	159
16	Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb interval. *Genes Chromosomes and Cancer*, **2004**, 41, 56-64	5	36
15	p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. *Molecular Cancer Therapeutics*, **2004**, 3, 895-902	6.1	86
14	High frequency of BRAF mutations in nevi. *Nature Genetics*, **2003**, 33, 19-20	36.3	1355
13	Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. *Nature Genetics*, **2003**, 34, 108-12	36.3	223
12	A genome-based strategy uncovers frequent BRAF mutations in melanoma. *Cancer Cell*, **2002**, 2, 5-7	24.3	128
11	PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. *Melanoma Research*, **2002**, 12, 565-75	3.3	55
10	Mutations in exon 3 of the beta-catenin gene are rare in melanoma cell lines. *Melanoma Research*, **2002**, 12, 183-6	3.3	31

9	CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin. *International Journal of Cancer*, **2001**, 93, 361-7	7.5	10
8	Mutation analysis of the CDKN2A promoter in Australian melanoma families. *Genes Chromosomes and Cancer*, **2001**, 32, 89-94	5	17
7	Molecular classification of cutaneous malignant melanoma by gene expression profiling. *Nature*, **2000**, 406, 536-40	50.4	1647
6	Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. *Human Mutation*, **1998**, 11, 424-31	4.7	49
5	Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. *Oncogene*, **1997**, 15, 2999-3005	9.2	74
4	CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. *International Journal of Cancer*, **1997**, 73, 531-6	7.5	37
3	Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. *Genes Chromosomes and Cancer*, **1996**, 15, 77-88	5	133
2	A homologue of the Drosophila Son of sevenless gene maps to mouse chromosome 17. *Genomics*, **1993**, 18, 733-4	4.3	1
1	Genomic analysis of patient-derived xenograft models reveals intra-tumor heterogeneity in endometrial cancer and can predict tumor growth inhibition with talazoparib		2